Medications causing female hair loss is a recognised but often overlooked side effect that can affect women taking a wide range of prescription and over-the-counter medicines. Known medically as drug-induced alopecia, this condition can arise from chemotherapy agents, hormonal therapies, anticoagulants, antidepressants, and several other drug classes. Understanding which medicines are implicated, how they affect the hair growth cycle, and what steps to take can help women seek timely, appropriate NHS care. This article provides UK-focused guidance on identifying, managing, and recovering from medication-related hair loss.
Summary: Medications causing female hair loss — known as drug-induced alopecia — can be triggered by a wide range of drugs including chemotherapy agents, anticoagulants, hormonal therapies, antidepressants, and retinoids, and should be reviewed by a GP or pharmacist before making any changes to treatment.
- Drug-induced alopecia occurs via two main mechanisms: telogen effluvium (delayed diffuse shedding, typically 2–4 months after the trigger) and anagen effluvium (rapid loss during active growth, characteristic of cytotoxic chemotherapy).
- Commonly implicated drug classes include chemotherapy agents, anticoagulants (e.g., warfarin, DOACs), hormonal contraceptives, HRT, antidepressants, retinoids, beta-blockers, and anticonvulsants such as sodium valproate.
- Never stop a prescribed medicine without medical advice; abrupt withdrawal of anticoagulants, anticonvulsants, or antidepressants can carry serious health risks.
- A GP medication review should include blood tests to exclude other causes — typically FBC, ferritin, TSH, and vitamin B12/folate — before attributing hair loss to a specific medicine.
- Topical minoxidil is available over the counter in the UK for female pattern hair loss, but should not be used during pregnancy or breastfeeding; consistent long-term use is required to maintain benefit.
- Suspected drug-induced hair loss can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
Table of Contents
- Which Medications Are Linked to Hair Loss in Women
- How Drug-Induced Hair Loss Develops
- Recognising the Signs and When to Seek NHS Advice
- Reviewing Your Medicines Safely With a GP or Pharmacist
- Treatment and Recovery Options Available in the UK
- Lifestyle Support and Further Resources
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Which Medications Are Linked to Hair Loss in Women
A wide range of medicines — including chemotherapy agents, anticoagulants, hormonal therapies, antidepressants, retinoids, beta-blockers, and anticonvulsants — have been reported to cause hair loss in women, with frequency varying by drug, dose, and individual factors.
Not sure if this is normal? Chat with one of our pharmacists →
A wide range of prescription and over-the-counter medicines have been reported in association with hair loss in women, a condition known medically as drug-induced alopecia. Not every woman taking these medicines will experience hair loss, and the frequency of this side effect varies considerably by drug, dose, formulation, and individual factors — ranging from rare to common depending on the specific product. Always check the patient information leaflet (PIL) supplied with your medicine, or the Summary of Product Characteristics (SmPC) available via the MHRA/EMC, for the reported frequency of alopecia for that product.
Medication groups for which alopecia has been reported as an adverse effect include:
-
Chemotherapy agents (e.g., cyclophosphamide, doxorubicin) — among the most well-recognised causes, often producing significant, rapid hair loss
-
Hormonal therapies, including combined hormonal contraceptives, progestogen-only pills, and hormone replacement therapy (HRT) — some preparations may influence hair density, though the clinical impact varies with formulation and individual susceptibility
-
Anticoagulants such as warfarin, heparin, and direct oral anticoagulants (DOACs, e.g., rivaroxaban, apixaban)
-
Antithyroid drugs (e.g., carbimazole, propylthiouracil)
-
Antidepressants and mood stabilisers, including lithium, fluoxetine, and sertraline — alopecia is listed in their SmPCs, though it is generally uncommon
-
Retinoids used for skin conditions (e.g., isotretinoin, acitretin)
-
Beta-blockers such as propranolol and atenolol
-
Anticonvulsants, including sodium valproate and carbamazepine
Medicines used to manage autoimmune conditions, such as methotrexate and hydroxychloroquine, may also contribute to hair thinning. The reported frequency of alopecia differs substantially between products and individuals.
If you think a medicine may be causing hair loss, you can report this to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk). This helps the MHRA monitor the safety of medicines in the UK. Do not stop any prescribed medicine without first speaking to your GP or pharmacist.
| Medication Group | Examples | Mechanism of Hair Loss | Onset | Severity | Action / Advice |
|---|---|---|---|---|---|
| Chemotherapy agents | Cyclophosphamide, doxorubicin | Anagen effluvium — direct damage to hair matrix cells | Within weeks of starting treatment | Often significant and widespread | Scalp cooling (cold cap) available at many NHS oncology centres; discuss with oncology team |
| Anticoagulants | Warfarin, heparin, rivaroxaban, apixaban | Telogen effluvium — follicles shift prematurely to resting phase | 2–4 months after starting | Variable; generally moderate | Do not stop without GP advice; medication review to assess alternatives |
| Hormonal therapies | Combined pill, progestogen-only pill, HRT | Androgenic progestogens may miniaturise follicles in susceptible women | Variable | Mild to moderate; patient-specific | Consider formulation change (e.g., lower androgenic activity or micronised progesterone) with clinician; follow FSRH guidance |
| Retinoids | Isotretinoin, acitretin | Telogen effluvium | 2–4 months after starting | Moderate; may be dose-related | Discuss dose reduction or alternative with prescriber; do not stop acitretin abruptly |
| Anticonvulsants | Sodium valproate, carbamazepine | Telogen effluvium; may be dose-related for valproate | 2–4 months after starting | Variable; dose-dependent for valproate | Never stop abruptly; GP review essential — dose reduction may help |
| Antidepressants & mood stabilisers | Lithium, fluoxetine, sertraline | Telogen effluvium; listed in SmPCs, mechanism not fully established | 2–4 months after starting | Generally uncommon and mild | Medication review with GP; do not stop antidepressants abruptly |
| Beta-blockers & antithyroid drugs | Propranolol, atenolol; carbimazole, propylthiouracil | Telogen effluvium | 2–4 months after starting | Variable; generally mild to moderate | GP review; blood tests (TSH, FBC, ferritin) to exclude concurrent thyroid or nutritional cause |
How Drug-Induced Hair Loss Develops
Drug-induced hair loss occurs via telogen effluvium (premature follicle resting, causing shedding 2–4 months later) or anagen effluvium (direct follicle damage during active growth, typical of chemotherapy); hormonal medicines may additionally miniaturise follicles through androgenic activity.
To understand how medicines cause hair loss, it helps to know a little about the normal hair growth cycle. Hair follicles pass through three phases: anagen (active growth), catagen (transition), and telogen (resting and shedding). Disruption to any of these phases can result in noticeable hair loss.
Drug-induced hair loss typically occurs through one of two mechanisms:
-
Telogen effluvium — the most common form, where a physiological stress (including certain medicines) causes a proportion of hair follicles to shift prematurely into the resting phase. Hair shedding becomes noticeable two to four months after the trigger, as the resting hairs are released. Anticoagulants, beta-blockers, retinoids, and some antidepressants have been reported to trigger this pattern, though the risk varies between individuals and products.
-
Anagen effluvium — a more acute and severe form, where rapidly dividing hair matrix cells are directly damaged during the active growth phase. This is characteristic of cytotoxic chemotherapy and can result in sudden, widespread hair loss within weeks of starting treatment.
Hormonal medicines may act differently, by influencing the androgen-to-oestrogen balance at the follicle level. Some progestogens have androgenic activity, which can miniaturise hair follicles in genetically susceptible women — a process similar to androgenetic alopecia (female pattern hair loss). However, the degree of androgenic activity varies considerably between progestogen types and formulations, and the clinical impact is patient-specific. This is one reason why changes to contraceptive or HRT formulations are sometimes considered in the context of hair changes, though any such decision should be made on an individual basis with a clinician.
For some medicines — particularly chemotherapy agents and sodium valproate — the severity of hair loss appears to be dose-related. For others, the relationship is less clear. Individual susceptibility also plays a role; women with a personal or family history of hair thinning may be more vulnerable to medication-related shedding, though the evidence base for this is still developing.
Recognising the Signs and When to Seek NHS Advice
Seek GP advice if you notice diffuse scalp thinning, increased shedding, or hair loss beginning 2–4 months after starting a new medicine; patchy loss, scalp redness, scarring, or loss of eyebrows warrants prompt dermatological review.
Drug-induced hair loss can be easy to overlook initially, as everyday shedding of 50–100 hairs is considered normal. However, certain signs suggest that hair loss may be more than routine and warrant professional assessment.
Signs that may indicate drug-induced hair loss include:
-
Noticeably increased hair on the pillow, in the shower drain, or on a hairbrush
-
Diffuse thinning across the scalp rather than a defined bald patch
-
A widening parting or visible reduction in ponytail thickness
-
Hair loss beginning two to four months after starting a new medicine (consistent with telogen effluvium)
-
Rapid, widespread shedding shortly after commencing chemotherapy
It is advisable to contact your GP if hair loss is causing distress, is progressing rapidly, or is accompanied by other symptoms such as fatigue, weight changes, or skin changes — as these may point to an underlying thyroid disorder, nutritional deficiency, or autoimmune condition that requires investigation. NICE Clinical Knowledge Summaries (CKS) on alopecia recommend a structured clinical assessment including a thorough medication history.
Seek prompt medical advice if you notice any of the following, as these may indicate conditions such as scarring alopecia (e.g., lichen planopilaris), alopecia areata, or other disorders requiring specialist dermatological review:
-
Patchy hair loss
-
Scalp redness, scaling, pustules, pain, or itch
-
Scarring or permanent-looking bald areas
-
Loss of eyebrows or eyelashes
These features may warrant an expedited referral to dermatology. NHS 111 can provide initial guidance if you are unsure whether your symptoms need urgent attention. Do not stop any prescribed medication without first speaking to your GP or pharmacist, as this may carry significant health risks.
Reviewing Your Medicines Safely With a GP or Pharmacist
A GP or clinical pharmacist should conduct a structured medication review — including blood tests to exclude other causes — before any medicine is altered; never stop prescribed drugs independently, as this can carry serious health risks.
If you suspect a medicine is contributing to hair loss, the most important first step is to arrange a medication review with your GP or a clinical pharmacist — never discontinue a prescribed medicine independently. Stopping certain drugs abruptly, such as anticoagulants, anticonvulsants, or antidepressants, can carry serious health consequences.
During a medication review, your clinician will typically:
-
Take a detailed history of when hair loss began in relation to when each medicine was started or its dose changed
-
Consider whether any recent additions to your regimen coincide with the onset of shedding
-
Review whether the suspected medicine is essential, or whether an alternative with a lower reported risk of alopecia might be appropriate for your circumstances
-
Request blood tests to help exclude other causes; first-line investigations commonly include full blood count (FBC), ferritin, thyroid function (TSH ± free T4), and vitamin B12/folate; vitamin D and a coeliac screen may be considered if there are relevant risk factors; androgen levels (total and free testosterone, SHBG) may be checked if there are clinical signs of hyperandrogenism
In some cases, a dose reduction may be sufficient to reduce hair loss whilst maintaining therapeutic benefit. For women on hormonal contraception or HRT, a change in formulation may sometimes be considered — for example, a combined hormonal contraceptive with lower androgenic activity, or a preparation containing micronised progesterone. However, any such change should be individualised, taking into account your contraceptive needs, medical history, and risk profile, in line with Faculty of Sexual and Reproductive Healthcare (FSRH) guidance and clinical judgement. There is no single formulation that is universally appropriate.
Community pharmacists are well placed to provide initial advice on whether a medicine is known to cause hair loss and can help facilitate a GP referral if needed. NHS medicines optimisation services increasingly include structured medication reviews, particularly for patients on multiple long-term medicines, and these can be a valuable opportunity to raise concerns about side effects including hair loss.
Experiencing these side effects? Our pharmacists can help you navigate them →
If you believe a medicine has caused hair loss, consider reporting this via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).
Treatment and Recovery Options Available in the UK
The primary treatment is modifying or stopping the causative medicine under medical supervision; telogen effluvium typically resolves within 3–6 months, while scalp cooling, topical minoxidil, and NHS dermatology referral are additional options depending on the cause.
The primary treatment for drug-induced hair loss is addressing the underlying cause — usually by modifying or discontinuing the offending medicine under medical supervision. In the case of telogen effluvium, hair regrowth typically begins within three to six months of removing the trigger, though full recovery may take up to a year.
For women undergoing chemotherapy, hair loss is often unavoidable, but scalp cooling (cold cap therapy) is available in many NHS oncology centres and has been shown to reduce the severity of chemotherapy-induced alopecia in some cases. Effectiveness varies depending on the chemotherapy regimen used, and your oncology team can advise on suitability. Macmillan Cancer Support provides UK-specific information on scalp cooling, including what to expect.
Where hair loss persists despite addressing the causative medicine, or where there is an underlying androgenetic component, the following options may be considered:
-
Topical minoxidil — available over the counter in the UK and licensed for female pattern hair loss. Formulations licensed for women include 5% foam (applied once daily) and 2% solution (applied twice daily); check the PIL or SmPC for the specific product you are using. An initial increase in shedding during the first few weeks is common and usually temporary. Local adverse effects can include scalp irritation and, rarely, unwanted facial hair. Topical minoxidil should not be used during pregnancy or breastfeeding; discuss with your GP or pharmacist if this applies to you. Consistent, long-term use is required to maintain benefit.
-
Referral to a consultant dermatologist or NHS dermatology-run hair clinic — for specialist assessment and management, particularly where the diagnosis is uncertain or hair loss is severe. If you choose to see a trichologist privately, be aware that this is not a protected medical title; seek practitioners registered with a recognised professional body and consider whether a medical opinion is also needed.
-
Nutritional supplementation — only where blood tests have confirmed a deficiency (e.g., ferritin, vitamin D, zinc); routine supplementation without confirmed deficiency is not supported by robust evidence.
-
NHS wigs and hair prostheses — women with certain medical conditions causing hair loss may be entitled to a wig on the NHS; your GP or specialist can advise on eligibility.
No medicine is currently licensed in the UK specifically for drug-induced alopecia. Treatment is therefore largely supportive and guided by clinical judgement. The British Association of Dermatologists (BAD) provides evidence-based guidance on alopecia management that informs NHS practice.
Lifestyle Support and Further Resources
A balanced diet, gentle hair care, and psychological support underpin recovery; high-dose biotin supplements should be avoided unless a deficiency is confirmed, as the MHRA warns they can interfere with thyroid and cardiac laboratory tests.
Whilst addressing the medical cause of hair loss is the priority, lifestyle measures can support scalp health and overall wellbeing during recovery. A balanced diet rich in protein, iron, and vitamins provides the nutritional foundation that hair follicles require. Women who follow restrictive diets or have conditions affecting nutrient absorption should discuss supplementation with their GP.
If you are considering biotin (vitamin B7) supplements, be aware that the MHRA has warned that high-dose biotin can interfere with certain laboratory tests — including thyroid function tests and cardiac troponin assays — potentially producing misleading results. Do not take high-dose biotin unless a deficiency has been confirmed, and inform your GP or the laboratory if you are taking biotin before having blood tests.
Gentle hair care practices can help minimise additional mechanical stress on fragile hair:
-
Avoid excessive heat styling, tight hairstyles, and harsh chemical treatments
-
Use a wide-toothed comb and handle wet hair with care
-
Allow hair to air-dry where possible
-
Choose mild shampoos and handle hair gently; there is no robust clinical evidence that shampoos marketed for thinning hair alter the course of hair loss
The psychological impact of hair loss should not be underestimated. Hair loss can significantly affect self-esteem, body image, and mental health, particularly in women. The NHS offers access to psychological support through GP referral. Organisations such as Alopecia UK provide peer support, information, and community resources specifically for people experiencing hair loss. For women undergoing cancer treatment, Macmillan Cancer Support and Maggie's Centres offer practical and emotional support relating to chemotherapy-induced hair loss.
For further reliable information, the following UK sources are recommended:
-
NHS.uk — patient information on hair loss and medicines
-
NICE Clinical Knowledge Summaries (CKS) — alopecia guidance for clinicians and patients (alopecia areata; female pattern hair loss)
-
British Association of Dermatologists (bad.org.uk) — patient leaflets on hair disorders including telogen effluvium and female pattern hair loss
-
Alopecia UK (alopecia.org.uk) — support and community resources
-
MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk) — to report suspected side effects of medicines
-
MHRA/EMC (medicines.org.uk) — SmPCs and PILs for individual medicines
Always consult a qualified healthcare professional before making any changes to your medicines or starting new treatments for hair loss.
Frequently Asked Questions
Which medications most commonly cause hair loss in women?
Chemotherapy agents are among the most well-recognised causes, but hair loss in women has also been reported with anticoagulants (e.g., warfarin, rivaroxaban), hormonal contraceptives, HRT, antidepressants, retinoids, beta-blockers, and anticonvulsants such as sodium valproate. The frequency and severity vary considerably between individual medicines and patients.
How long does it take for hair to regrow after stopping a medication that caused hair loss?
In cases of telogen effluvium, hair regrowth typically begins within three to six months of removing the causative medicine, though full recovery can take up to a year. Always discuss stopping or changing any prescribed medicine with your GP or pharmacist before making any changes.
Should I stop taking my medication if I think it is causing hair loss?
No — never stop a prescribed medicine without first speaking to your GP or pharmacist. Abruptly discontinuing certain drugs, such as anticoagulants, anticonvulsants, or antidepressants, can carry serious health risks. A clinician can review your medicines safely and explore alternatives if appropriate.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
